Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.58 |
| ▸ | PLG | P00747 | 2/20 | 0.58 |
| ▸ | PLAT | P00750 | 2/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 3/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837207 | 1.00 | PLAU (0.58) | PLAUPLGPLATHSD17B2MAPT | |
| SCHEMBL4322553 | 0.90 | MAPT (0.59) | PLAUPLGPLATHSD17B2MAPT | |
| SCHEMBL30837176 | 0.88 | HSD17B2 (0.61) | HSD17B2HDAC4HDAC8CES2CES1 | |
| SCHEMBL30278441 | 0.86 | RXRA (0.72) | PLAUPLGPLATHSD17B2TRPV1 | |
| SCHEMBL505652 | 0.86 | RXRA (0.72) | PLAUPLGPLATHSD17B2TRPV1 | |
| Acetic Acid SCHEMBL28960935 | 0.85 | HDAC4 (0.61) | PLAUPLGPLATHSD17B2TRPV1 | |
| SCHEMBL6637315 | 0.85 | PLAU (0.57) | PLAUPLGPLATHSD17B2TRPV1 | |
| SCHEMBL30958376 | 0.85 | PLAU (0.67) | PLAUPLGPLATHSD17B2TRPV1 | |
| SCHEMBL4995249 | 0.85 | PLAU (0.67) | PLAUPLGPLATHSD17B2TRPV1 | |
| SCHEMBL6716525 | 0.85 | PLAU (0.60) | PLAUPLGPLATHSD17B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1924539-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | Saltigo GmbH (DE) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007031511-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | SALTIGO GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031511-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | SALTIGO GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | PLAU 3012/4885PLG 1214/4885PLAT 1450/4885 |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | MON2, ZRANB2, GRIA2 | PLAU 4743/4885PLG 4580/4885PLAT 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.